<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03233139</url>
  </required_header>
  <id_info>
    <org_study_id>R2810-ONC-1622</org_study_id>
    <nct_id>NCT03233139</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase 1 Study to Investigate the Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety, tolerability, and
      Pharmacokinetics (PK) of REGN2810 in Japanese patients with advanced malignancies. The
      secondary objective of the study is to assess the immunogenicity of REGN2810.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs) in patients treated with REGN2810</measure>
    <time_frame>Up to 136 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of REGN2810: Cmax</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>Peak serum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of REGN2810: tmax</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>Time to Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of REGN2810: Ctrough</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>Drug concentration in serum at the end of a dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of REGN2810: Area under the drug concentration-time curve in serum AUC3w</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>AUC over a 3-week dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of REGN2810: t½ estimated over a 3-week dosing interval</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>Observed terminal half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity against REGN2810</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>Evaluate the immunogenicity of REGN2810 after single-dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 135 weeks</time_frame>
    <description>As assessed by an Independent Review Committee (IRC) using RECIST 1.1 (Eisenhauer 2009) in Part 2, Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 136 weeks</time_frame>
    <description>As assessed by an IRC (per RECIST1.1) in Part 2, Cohort A</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>REGN2810</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN2810</intervention_name>
    <description>Patients will be administered REGN2810 as per protocol</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>REGN2810</arm_group_label>
    <other_name>cemiplimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>To be administered per protocol</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum-doublet chemotherapy</intervention_name>
    <description>To be administered per protocol</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Disease types under study:

               -  Part 1: Histologically or cytologically confirmed diagnosis of malignancy with no
                  alternative standard-of-care therapeutic option

               -  Part 2: Patients with histologically or cytologically documented squamous or
                  non-squamous NSCLC with stage IIIB or stage IV disease who received no prior
                  systemic treatment for recurrent or metastatic NSCLC.

               -  Patients in Part 2 NSCLC cohorts must have available archival or newly obtained
                  formalin-fixed tumor tissue from a metastatic/recurrent site, which has not
                  previously been irradiated.

          2. ECOG (Eastern Cooperative Oncology Group) PS (Performance status) ≤1 (Restricted in
             physically strenuous activity but ambulatory and able to carry out work of a light or
             sedentary nature [eg, light house work or office work]). Note: Patients with ECOG PS
             &gt;1 are ineligible.

          3. Patients must have been born in Japan, and their biological parents and grandparents
             must all have been of Japanese origin

          4. Willing and able to comply with clinic visits and study-related procedures

        Key Exclusion Criteria:

          1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that
             requires treatment with systemic immunosuppressive treatments, which may suggest risk
             for Immune-related adverse event (irAE)s. The following are not exclusionary:
             vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires
             only hormone replacement or psoriasis that does not require systemic treatment.

          2. Untreated brain metastasis (es) that may be considered active. Patients with
             previously treated brain metastases may participate provided they are stable, there is
             no evidence of new or enlarging brain metastases, and the patient does not require any
             systemic corticosteroids for management of brain metastases within 4 weeks prior to
             the first dose of REGN2810.

          3. Immunosuppressive corticosteroid doses (&gt;10 mg prednisone daily or equivalent) within
             4 weeks prior to the first dose of REGN2810.

          4. Any positive test (ribonucleic acid (RNA) or Deoxyribonucleic acid (DNA) by polymerase
             chain reaction) for hepatitis B, hepatitis C, or human immunodeficiency virus
             indicating uncontrolled active or chronic infection.

          5. History of pneumonitis or interstitial lung disease

          6. Surgery within 1 month of first dose and radiation therapy within 2 weeks of first
             dose

          7. Completed palliative radiation therapy within the prior 2 weeks or has not recovered
             from any medically significant radiation-related Adverse Event (AE)

          8. Patients that have never smoked, defined as smoking ≤100 cigarettes in a lifetime
             (Part 2)

          9. Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene
             mutations, anaplastic lymphoma kinase (ALK) gene translocations, or ROS1 fusions (Part
             2)

        Note: Other protocol defined inclusion/exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cardiovascular and Respiratory Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sasebo City General Hospital</name>
      <address>
        <city>Sasebo</city>
        <state>Nagasaki</state>
        <zip>857-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>710-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka Medical College Hospital</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinki-Chuo Chest Medical Center</name>
      <address>
        <city>Sakai</city>
        <state>Osak</state>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Kita Adachi</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Cho-Ku</city>
        <state>Tokyo</state>
        <zip>104-0055</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gunma Prefectural Cancer Center</name>
      <address>
        <city>Gunma</city>
        <zip>373-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hiroshima Citizens Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Center</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokushima University Hospital</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 25, 2017</study_first_submitted>
  <study_first_submitted_qc>July 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

